Welcome to our dedicated page for Freeline Therapeutics Holdings Plc news (Ticker: FRLN), a resource for investors and traders seeking the latest updates and insights on Freeline Therapeutics Holdings Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Freeline Therapeutics Holdings Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Freeline Therapeutics Holdings Plc's position in the market.
Freeline Therapeutics announced the pricing of its initial public offering (IPO) in the U.S., offering 8,823,529 American Depositary Shares (ADSs) at $18.00 each, raising approximately $158.8 million. All ADSs are sold by Freeline. The shares will start trading on Nasdaq under ticker symbol FRLN on August 7, 2020. Additionally, the underwriters have a 30-day option to purchase 1,323,529 ADSs at the IPO price. The offering is set to close on August 11, 2020, pending customary conditions.
Freeline Therapeutics Holdings has launched a roadshow for its initial public offering (IPO) in the U.S. for up to 7,352,941 American Depositary Shares (ADSs) priced between $16.00 and $18.00 per ADS, targeting a total offering size of $117.6 million to $132.4 million. This offering includes a 30-day option for underwriters to purchase an additional 1,102,941 ADSs. Freeline aims to list its ADSs on The Nasdaq under the ticker symbol FRLN. The IPO is managed by J.P. Morgan, Morgan Stanley, and Evercore.